-DOCSTART- -X- O
A -X- _ O
Quantitative -X- _ O
Structure-Activity -X- _ O
Relationship -X- _ O
( -X- _ O
QSAR -X- _ O
) -X- _ O
approach -X- _ O
for -X- _ O
classification -X- _ O
was -X- _ O
used -X- _ O
for -X- _ O
the -X- _ O
prediction -X- _ O
of -X- _ O
compounds -X- _ O
as -X- _ O
active -X- _ O
/ -X- _ O
inactive -X- _ O
relatively -X- _ O
to -X- _ O
overall -X- _ O
biological -X- _ O
activity -X- _ O
, -X- _ O
antitumor -X- _ O
and -X- _ O
antibiotic -X- _ O
activities -X- _ O
using -X- _ O
a -X- _ O
data -X- _ O
set -X- _ O
of -X- _ O
1746 -X- _ B-Patient
compounds -X- _ I-Patient
from -X- _ I-Patient
PubChem -X- _ I-Patient
with -X- _ I-Patient
empirical -X- _ I-Patient
CDK -X- _ I-Patient
descriptors -X- _ I-Patient
and -X- _ I-Patient
semi-empirical -X- _ I-Patient
quantum-chemical -X- _ I-Patient
descriptors. -X- _ I-Patient
A -X- _ B-Intervention
data -X- _ I-Intervention
set -X- _ I-Intervention
of -X- _ I-Intervention
183 -X- _ I-Intervention
active -X- _ I-Intervention
pharmaceutical -X- _ I-Intervention
ingredients -X- _ I-Intervention
was -X- _ I-Intervention
additionally -X- _ I-Intervention
used -X- _ I-Intervention
for -X- _ I-Intervention
the -X- _ I-Intervention
external -X- _ I-Intervention
validation -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
best -X- _ I-Intervention
models. -X- _ I-Intervention
The -X- _ O
best -X- _ O
classification -X- _ O
models -X- _ O
for -X- _ O
antibiotic -X- _ O
and -X- _ O
antitumor -X- _ O
activities -X- _ O
were -X- _ O
used -X- _ O
to -X- _ O
screen -X- _ O
a -X- _ B-Comparison
data -X- _ I-Comparison
set -X- _ I-Comparison
of -X- _ I-Comparison
marine -X- _ I-Comparison
and -X- _ I-Comparison
microbial -X- _ I-Comparison
natural -X- _ I-Comparison
products -X- _ I-Comparison
from -X- _ I-Comparison
the -X- _ I-Comparison
AntiMarin -X- _ I-Comparison
databaseâ€”25 -X- _ I-Comparison
and -X- _ I-Comparison
four -X- _ I-Comparison
lead -X- _ I-Comparison
compounds -X- _ I-Comparison
for -X- _ I-Comparison
antibiotic -X- _ I-Comparison
and -X- _ I-Comparison
antitumor -X- _ I-Comparison
drug -X- _ I-Comparison
design -X- _ I-Comparison
were -X- _ I-Comparison
proposed -X- _ I-Comparison
, -X- _ I-Comparison
respectively. -X- _ I-Comparison
The -X- _ B-Outcome
present -X- _ I-Outcome
work -X- _ I-Outcome
enables -X- _ I-Outcome
the -X- _ I-Outcome
presentation -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
new -X- _ I-Outcome
set -X- _ I-Outcome
of -X- _ I-Outcome
possible -X- _ I-Outcome
lead -X- _ I-Outcome
like -X- _ I-Outcome
bioactive -X- _ I-Outcome
compounds -X- _ I-Outcome
and -X- _ I-Outcome
corroborates -X- _ I-Outcome
the -X- _ I-Outcome
results -X- _ I-Outcome
of -X- _ I-Outcome
our -X- _ I-Outcome
previous -X- _ I-Outcome
investigations. -X- _ I-Outcome
By -X- _ I-Outcome
other -X- _ I-Outcome
side -X- _ I-Outcome
it -X- _ I-Outcome
is -X- _ I-Outcome
shown -X- _ I-Outcome
the -X- _ I-Outcome
usefulness -X- _ I-Outcome
of -X- _ I-Outcome
quantum-chemical -X- _ I-Outcome
descriptors -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
discrimination -X- _ I-Outcome
of -X- _ I-Outcome
biologically -X- _ I-Outcome
active -X- _ I-Outcome
and -X- _ I-Outcome
inactive -X- _ I-Outcome
compounds. -X- _ I-Outcome
None -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
compounds -X- _ I-Outcome
suggested -X- _ I-Outcome
by -X- _ I-Outcome
our -X- _ I-Outcome
approach -X- _ I-Outcome
have -X- _ I-Outcome
assigned -X- _ I-Outcome
non-antibiotic -X- _ I-Outcome
and -X- _ I-Outcome
non-antitumor -X- _ I-Outcome
activities -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
AntiMarin -X- _ I-Outcome
database -X- _ I-Outcome
and -X- _ I-Outcome
almost -X- _ I-Outcome
all -X- _ I-Outcome
were -X- _ I-Outcome
lately -X- _ I-Outcome
reported -X- _ I-Outcome
as -X- _ I-Outcome
being -X- _ I-Outcome
active -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
literature -X- _ I-Outcome
. -X- _ O

